Altamira Therapeutics (CYTO) Competitors $0.30 -0.11 (-25.94%) (As of 12/19/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends CYTO vs. GTBP, HOTH, CANF, ELAB, IMCC, BMRA, AEZS, PPBT, BNOX, and UPXIShould you be buying Altamira Therapeutics stock or one of its competitors? The main competitors of Altamira Therapeutics include GT Biopharma (GTBP), Hoth Therapeutics (HOTH), Can-Fite BioPharma (CANF), Elevai Labs (ELAB), IM Cannabis (IMCC), Biomerica (BMRA), Aeterna Zentaris (AEZS), Purple Biotech (PPBT), Bionomics (BNOX), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Altamira Therapeutics vs. GT Biopharma Hoth Therapeutics Can-Fite BioPharma Elevai Labs IM Cannabis Biomerica Aeterna Zentaris Purple Biotech Bionomics Upexi Altamira Therapeutics (NASDAQ:CYTO) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Which has stronger valuation and earnings, CYTO or GTBP? Altamira Therapeutics has higher revenue and earnings than GT Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltamira Therapeutics$320K3.19-$4.31MN/AN/AGT BiopharmaN/AN/A-$7.60MN/AN/A Do analysts recommend CYTO or GTBP? GT Biopharma has a consensus target price of $11.00, indicating a potential upside of 530.37%. Given GT Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe GT Biopharma is more favorable than Altamira Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altamira Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility & risk, CYTO or GTBP? Altamira Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Does the media favor CYTO or GTBP? In the previous week, Altamira Therapeutics had 1 more articles in the media than GT Biopharma. MarketBeat recorded 2 mentions for Altamira Therapeutics and 1 mentions for GT Biopharma. Altamira Therapeutics' average media sentiment score of 0.99 beat GT Biopharma's score of 0.92 indicating that Altamira Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altamira Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CYTO or GTBP? 1.9% of Altamira Therapeutics shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 13.0% of Altamira Therapeutics shares are held by insiders. Comparatively, 10.9% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer CYTO or GTBP? GT Biopharma received 117 more outperform votes than Altamira Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAltamira TherapeuticsN/AN/AGT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% Is CYTO or GTBP more profitable? Altamira Therapeutics' return on equity of 0.00% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Altamira TherapeuticsN/A N/A N/A GT Biopharma N/A -257.47%-131.09% SummaryAltamira Therapeutics beats GT Biopharma on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Altamira Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTO vs. The Competition Export to ExcelMetricAltamira TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / Sales3.19195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book0.075.094.784.78Net Income-$4.31M$151.83M$120.31M$225.60M7 Day Performance-30.88%-2.13%-1.92%-1.23%1 Month Performance-31.43%-3.10%11.51%3.36%1 Year Performance-90.94%11.54%30.61%16.60% Altamira Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTOAltamira Therapeutics1.9288 of 5 stars$0.30-25.9%N/A-90.9%$1.02M$320,000.000.0020News CoverageGap UpGTBPGT Biopharma3.6571 of 5 stars$2.51-8.7%$11.00+338.2%-78.3%$5.61MN/A0.008Positive NewsGap UpHOTHHoth Therapeutics2.0112 of 5 stars$0.81flat$3.50+332.1%-30.8%$5.59MN/A-0.614Gap UpCANFCan-Fite BioPharma1.7928 of 5 stars$1.51-4.4%$14.00+827.2%-30.7%$5.35M$667,000.00-0.888ELABElevai Labs0.3455 of 5 stars$2.06-10.0%N/A-99.3%$5.33M$2.45M-0.0318News CoverageGap DownIMCCIM Cannabis0.0474 of 5 stars$2.38-3.6%N/A+3.4%$5.31M$51.39M-0.72340Gap DownBMRABiomerica0.142 of 5 stars$0.31-1.2%N/A-76.8%$5.22M$5.51M-0.8260Gap DownAEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst ForecastPPBTPurple Biotech1.6721 of 5 stars$3.88+1.3%$33.00+750.5%N/A$5.16MN/A-0.4720BNOXBionomics2.5163 of 5 stars$0.29-12.3%$8.00+2,707.0%-81.3%$5.03M$10,000.000.00N/AUPXIUpexi2.3432 of 5 stars$4.77-2.7%$25.00+424.1%-79.2%$4.98M$83.98M0.00130Earnings ReportPositive NewsGap Down Related Companies and Tools Related Companies GTBP Alternatives HOTH Alternatives CANF Alternatives ELAB Alternatives IMCC Alternatives BMRA Alternatives AEZS Alternatives PPBT Alternatives BNOX Alternatives UPXI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altamira Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTO Stock Alerts